Physician profile
Carol Walker
NPI 1396769428
$3,264.63
in general payments reported to CMS, 2019-2025
32 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $690 · 2023: $683 · 2024: $735 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $449.53 | 2021-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $325.78 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $278.52 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $228.39 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $211.07 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.56 | 2021-2024 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $187.26 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $177.12 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $124.60 | 2021 | |
| Xeris Pharmaceuticals, INC. | $118.03 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $100.25 | 2023-2025 | Rexulti |
| Pfizer INC. | $82.89 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.42 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $71.67 | 2022-2025 | Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $69.42 | 2022-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $68.46 | 2022-2023 | Belsomra, Steglatro |
| Abbott Laboratories | $64.32 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $62.69 | 2024-2025 | |
| Exact Sciences Corporation | $56.19 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.22 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Phathom Pharmaceuticals, INC. | $34.26 | 2024 | Voquezna |
| Mylan Specialty L.P. | $33.03 | 2022 | |
| Boston Scientific Corporation | $32.09 | 2025 | General - Pain Management |
| Esperion Therapeutics, INC. | $25.74 | 2025 | Nexletol |
| Corcept Therapeutics | $24.12 | 2025 | Korlym |
| Dynavax Technologies Corporation | $22.62 | 2025 | Heplisav-B |
| Inspire Medical Systems, INC. | $18.11 | 2025 | Inspire |
| Cranial Technologies, INC | $14.94 | 2023 | Doc Band |
| Novartis Pharmaceuticals Corporation | $14.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.96 | 2021 | |
| Shield Therapeutics INC | $13.54 | 2025 | |
| Idorsia Pharmaceuticals US INC | $12.78 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.